Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
May 06, 2024 06:25 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power...
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
February 08, 2024 05:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of...
Genenta to Present at Upcoming Scientific and Investor Conferences
September 06, 2023 07:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
July 28, 2023 03:00 ET
|
GENENTA SCIENCE SPA
Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science...
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
June 29, 2023 07:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...
Genenta to Provide Update on Lead Product Temferon™
May 16, 2023 07:00 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage...
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
April 26, 2023 07:00 ET
|
GENENTA SCIENCE SPA
Funds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN,...